Hikma Pharmaceuticals' FY26 Operating Profit Outlook Narrowed

MT Newswires · 4d ago
02:39 AM EST, 11/05/2026 (MT Newswires) -- Hikma Pharmaceuticals (HIK.L) made adjustments to its group operating profit guidance for full-year 2026 with its latest trading update. The London-listed drugmaker said Thursday it expects group operating profit to be in the range of $740 million to $760 million, compared with its previous forecast of between $720 million and $770 million. However, the company continues to expect group revenue growth of between 2% and 4% for the year.